A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma
In an abstract release for the the 2023 annual meeting of the Society for Immunotherapy of Cancer, the Johns Hopkins University team released the initial results of their peptide vaccine clinical trial launched in 2020. The trial investigated the potential effectiveness of a targeted vaccine against FLC’s DNAJ-PKAc driver when combined with the checkpoint inhibitors …